CAMBRIDGE, Mass., February 25, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy ...

Scholar Rock’s spinal muscular atrophy (SMA) therapy has shown benefit in muscle function in children under 12 in a pivotal study, but investors are not impressed. The Phase III SAPPHIRE trial ...

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders ...

Also Read: Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth The topline data released in October 2024 showed the study achieved its primary ...

A number of brokerages recently issued reports on SRRK. HC Wainwright increased their target price on Scholar Rock from $40.00 to $50.00 and gave the stock a “buy” rating in a report on ...

Scholar Rock (SRRK) announced that new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial will be presented in multiple clinical presentations at the 2025 Muscular Dystrophy ...

China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug Future of Healthcategory· November 20, 2024 Scholar Rock's experimental drug achieved its main target in a ...

TD Cowen analyst Marc Frahm maintained a Buy rating on Scholar Rock Holding (SRRK – Research Report) today. The company’s shares closed last Friday at $34.60. Easily identify stocks' risks and ...

Investors considering a purchase of Scholar Rock Holding Corp (Symbol: SRRK) stock, but cautious about paying the going market price of $37.22/share, might benefit from considering selling puts ...